Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion

Dear Visitor, We are sorry, but the global website of Bayer AG is currently not available.
Please try again in a few minutes. We apologize for any inconvenience caused.

In the meantime, you might find the following links and social media channels useful:

Half-Year Financial Report 2023

English: PDF, 442 KB
German: PDF, 460 KB

Quarterly Statement 1st Quarter 2023

English: PDF, 245 KB
German: PDF, 239 KB

Bayer AG Annual Stockholders’ Meeting 2023

English: video recording
German: Aufzeichnung

Annual Report 2022:

English: PDF, 4.68 KB
German: PDF, 3.72 KB
English: webcast

Bayer AG Financial Statements 2022:

English: PDF, 399 KB
German: PDF, 437 KB

Sustainability Report 2022:

English: PDF, 6.23 KB
German: PDF, 6.14 KB

Quarterly Statement 3rd Quarter 2022

English: PDF, 231 KB
German: PDF, 267 KB
English: webcast

Global Social Media Channels:




Read More

Leave a Reply

Your email address will not be published. Required fields are marked *